M&A Deal Summary |
|
|---|---|
| Date | 2023-09-19 |
| Target | Precision Pathology Services - Laboratory Assets |
| Sector | Healthcare Services |
| Buyer(s) | bioAffinity |
| Sellers(s) | Precision Pathology |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2014 |
| Sector | Life Science |
| Employees | 57 |
| Revenue | 9M USD (2024) |
bioAffinity is a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer. bioAffinity was founded in 2014 and is based in San Antonio, Texas.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Healthcare Services M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Texas M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 1986 |
| Sector | Healthcare Services |
Precision Pathology provides pathology services to physicians practicing in a variety of outpatient settings and has offered bioAffinity Technologies’ CyPath® Lung as a laboratory developed test for the detection of early-stage lung cancer. Precision Pathology was founded in 1986 and is based in San Antonio, Texas.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Healthcare Services M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Texas M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |
